ATRA

9.60

10.09% 0.88

Handel nachbörslich: 9.60

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$8.72

Offen:

$8.85

24-Stunden-Volumen:

79,145

Relative Volume:

0.89

Marktkapitalisierung:

$96.36M

Einnahmen:

$23.14M

Nettoeinkommen (Verlust:

$-9.47M

KGV:

-10.88

EPS:

-0.8827

Netto-Cashflow:

$-25.88M

1W Leistung:

+4.07%

1M Leistung:

+14.42%

6M Leistung:

+126.42%

1J Leistung:

-16.38%

1-Tages-Spanne:

$8.2764

$9.74

1-Wochen-Bereich:

$7.73

$9.74

52-Wochen-Spanne:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1078)

Branche

Biotechnology (605)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

Twitter

@Atarabio

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	9.60	87.53M	23.14M	-9.47M	-25.88M	-0.8827
VRTX Vertex Pharmaceuticals Inc	552.06	133.88B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	840.84	83.42B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	174.38	25.14B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	1,032.86	62.12B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	214.66	46.30B	742.00K	-1.37B	-1.07B	-7.0731

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-13	Herabstufung	Canaccord Genuity	Buy → Hold
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

Aug 18, 2026

Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - Vinanet

Aug 18, 2026

Aug 16, 2026

ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 16, 2026

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat

Aug 16, 2026

Aug 15, 2026

Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Aug 15, 2026

Aug 14, 2026

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria

Aug 13, 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace

Aug 13, 2026

Aug 12, 2026

Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade

Aug 12, 2026

Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus

Aug 12, 2026

Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat

Aug 12, 2026

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView

Aug 12, 2026

Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com

Aug 12, 2026

BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView

Aug 12, 2026

Aug 11, 2026

Atara Biotherapeutics (ATRA) Rallies 3.8% to $8.94, Approaching Resistance at $9.39Negative Gamma - Vinanet

Aug 11, 2026

Aug 10, 2026

Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media

Aug 10, 2026

Aug 08, 2026

ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review

Aug 08, 2026

Atara Biotherapeutics (NASDAQ:ATRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Aug 08, 2026

Aug 07, 2026